ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 48 filers reported holding ALPINE IMMUNE SCIENCES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,660 | +11.4% | 1,193,030 | 0.0% | 0.59% | +54.2% |
| Q2 2023 | $12,264 | +33.2% | 1,193,030 | 0.0% | 0.38% | -30.5% |
| Q1 2023 | $9,210 | +5.0% | 1,193,030 | 0.0% | 0.55% | +11.9% |
| Q4 2022 | $8,769 | -99.9% | 1,193,030 | 0.0% | 0.49% | +33.2% |
| Q3 2022 | $8,590,000 | +70.2% | 1,193,030 | +101.2% | 0.37% | +35.9% |
| Q2 2022 | $5,047,000 | -5.1% | 593,030 | 0.0% | 0.27% | +21.1% |
| Q1 2022 | $5,319,000 | -35.2% | 593,030 | 0.0% | 0.22% | 0.0% |
| Q4 2021 | $8,213,000 | +29.8% | 593,030 | 0.0% | 0.22% | +57.0% |
| Q3 2021 | $6,328,000 | +18.6% | 593,030 | 0.0% | 0.14% | +31.5% |
| Q2 2021 | $5,337,000 | -15.1% | 593,030 | 0.0% | 0.11% | -2.7% |
| Q1 2021 | $6,286,000 | -15.9% | 593,030 | 0.0% | 0.11% | -30.6% |
| Q4 2020 | $7,472,000 | +43.3% | 593,030 | 0.0% | 0.16% | +26.0% |
| Q3 2020 | $5,213,000 | – | 593,030 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 2,571,450 | $23,143,000 | 2.13% |
| Omega Fund Management, LLC | 1,284,900 | $11,564,000 | 1.31% |
| Avidity Partners Management LP | 1,495,000 | $13,455,000 | 0.36% |
| Samsara BioCapital, LLC | 275,169 | $2,477,000 | 0.31% |
| Orbimed Advisors | 3,070,955 | $27,639,000 | 0.28% |
| Ikarian Capital, LLC | 300,454 | $2,704,000 | 0.22% |
| TIGER MANAGEMENT L.L.C. | 137,728 | $1,240,000 | 0.22% |
| DAFNA Capital Management LLC | 113,302 | $1,020,000 | 0.21% |
| EcoR1 Capital, LLC | 522,635 | $4,704,000 | 0.18% |
| Artal Group S.A. | 593,030 | $5,337,000 | 0.11% |